ARTICLE | Company News
Oxford BioTherapeutics, Boehringer Ingelheim deal
May 2, 2016 7:00 AM UTC
Boehringer exercised a second option under a 2013 deal with Oxford and will receive exclusive rights to an undisclosed cancer target. Boehringer will be responsible for developing and commercializing ...